[Articles] Safety, tolerability, and immunogenicity of an adult pneumococcal conjugate vaccine, V116 (STRIDE-3): a randomised, double-blind, active comparator controlled, international phase 3 trial

Di |2024-07-02T00:30:02+02:00Luglio 2nd, 2024|Categorie: Coronavirus Lancet|

V116 was non-inferior to PCV20 for the ten serotypes common to both vaccines and superior to PCV20 for all serotypes unique to V116, except for 15C. Immune responses successfully immunobridged between younger and older adults for all serotypes in V116....

[Corrections] Correction to Lancet Infect Dis 2024; published online Feb 9. https://doi.org/10.1016/S1473-3099(23)00731-4

Di |2024-06-28T00:30:01+02:00Giugno 28th, 2024|Categorie: Coronavirus Lancet|

Chang CC, Harrison TS, Bicanic TA, et al. Global guideline for the diagnosis and management of cryptococcosis: an initiative of the ECMM and ISHAM in cooperation with the ASM. Lancet Infect Dis 2024; published online Feb 9. https://doi.org/10.1016/S147...

[Correspondence] Advocating for inclusive respiratory syncytial virus vaccine trials to address health disparities

Di |2024-06-21T00:30:01+02:00Giugno 21st, 2024|Categorie: Coronavirus Lancet|

In the 2024 study by Ann R Falsy and colleagues, the Ad26.RSV.preF–RSV preF protein vaccine offered strong protection against respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in healthy adults aged 65 years or older (84·1%) and ...

Torna in cima